{
    "name": "Definitions",
    "number": "91",
    "text": "PART VI.\u00a0 DRUG PRODUCT SELECTION\n\u00a0\nCross References\n\u00a0\n\u00a0 Pharmacy benefit managers; health information; prohibited marketing practices, see \u00a7487J-7.\n\u00a0 Prescription drug benefits, see chapter 431R.\n\u00a0 Prescription drugs; mail order opt out option, see \u00a787A-16.3.\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0 As used in this part:\n\u00a0\u00a0\u00a0\u00a0 \"Agent\" means a person under the direct supervision of a pharmacist, acting in the pharmacist's presence.\n\u00a0\u00a0\u00a0\u00a0 \"Bioequivalents\" means chemical equivalents which, when administered to the same individuals in the same dosage regimen, will result in comparable bioavailability, as defined by the Federal Food and Drug Administration.\n\u00a0\u00a0\u00a0\u00a0 \"Board\" means the drug product selection board.\n\u00a0\u00a0\u00a0\u00a0 \"Compendia of therapeutically equivalent generic drug products\" means the Orange Book and any United States Food and Drug Administration documentation of any United States Food and Drug Administration-approved generic drug product with therapeutic equivalency evaluations, including but not limited to:\n\u00a0\u00a0\u00a0\u00a0 (1)\u00a0 Letters of approval of Abbreviated New Drug Applications with therapeutic equivalency evaluations;\n\u00a0\u00a0\u00a0\u00a0 (2)\u00a0 Published listings of approved New Drug Applications or approved Abbreviated New Drug Applications with therapeutic equivalency evaluations; and\n\u00a0\u00a0\u00a0\u00a0 (3)\u00a0 Listings of first time generics with therapeutic equivalency evaluations, adopted by the director.\n\u00a0\u00a0\u00a0\u00a0 \"Equivalent generic drug product\" means a drug product with the same established name, active ingredient strength, quantity, and dosage form as the drug product identified in the prescription, and:\u00a0 (1) that is listed as therapeutically equivalent (i.e., addition) in the current Hawaii additions and deletions list; or (2) that is listed in the compendia of therapeutically equivalent generic drug products and is not listed as therapeutically inequivalent (i.e., deletion) in the Hawaii additions and deletions list.\n\u00a0\u00a0\u00a0\u00a0 \"Hawaii additions and deletions list\" means:\n\u00a0\u00a0\u00a0\u00a0 (1)\u00a0 A list of drug products that the board has determined to be safe, effective, and therapeutically equivalent generic drug products but are not in the compendia of therapeutically equivalent generic drugs; and\n\u00a0\u00a0\u00a0\u00a0 (2)\u00a0 A list of drug products that are included in the compendia of therapeutically equivalent generic drugs, but that the board has determined not to be safe, effective, therapeutically equivalent, or bioequivalent generic drug products.\n\u00a0\u00a0\u00a0\u00a0 \"Maximum allowable cost\" means the maximum amount that a pharmacy benefit manager shall reimburse a pharmacy for the cost of a drug.\n\u00a0\u00a0\u00a0\u00a0 \"Maximum allowable cost list\" means a list of drugs for which a maximum allowable cost has been established by a pharmacy benefit manager.\n\u00a0\u00a0\u00a0\u00a0 \"Multiple source drug\" means a drug marketed or sold by two or more manufacturers or labelers or a drug marketed or sold by the same manufacturer or labeler under two or more different brand names, or both, under a brand name and without such a name.\n\u00a0\u00a0\u00a0\u00a0 \"Obsolete\" means a drug that may be listed in a national drug pricing compendia but cannot be dispensed based on the expiration date of the last lot manufactured.\n\u00a0\u00a0\u00a0\u00a0 \"Orange Book\" means the United States Food and Drug Administration's \"Approved Drug Products with Therapeutic Equivalence Evaluations\" publication and its cumulative supplements, which include a list of approved prescription drug products with therapeutic equivalence evaluations.\n\u00a0\u00a0\u00a0\u00a0 \"Savings\" means the financial benefit derived from utilizing the substituted equivalent generic drug product from the perspective of the consumer or the ultimate payer, including third party payers.\n\u00a0\u00a0\u00a0\u00a0 \"United States Food and Drug Administration-approved generic drug product with therapeutic equivalency evaluations\" means a generic drug product approved for marketing by the United States Food and Drug Administration pursuant to 21 C.F.R. Part 314 and with established bioequivalency to the referenced brand drug pursuant to 21 C.F.R. Part 320. [L 1980, c 187, pt of \u00a71; am L 1982, c 122, \u00a71(3); am L 1996, c 209, \u00a72; am L 1997, c 214, \u00a710; am L 1999, c 209, \u00a71; am L 2003, c 56, \u00a75; am L 2004, c 28, \u00a72; am L 2015, c 175, \u00a72]"
}